Dr. York is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3601 Pierce Ave
Nashville, TN 37232Phone+1 615-936-2000Fax+1 615-936-0605
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 1999 - 2001- Duke University HospitalResidency, Internal Medicine, 1996 - 1999
Washington University in St. Louis School of MedicineClass of 1996
Certifications & Licensure
TN State Medical License 2012 - 2026
AL State Medical License 2020 - 2020
NC State Medical License 1997 - 2013- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Start of enrollment: 2016 Jan 25
- Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
- Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 93 citationsLongitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease RelapseKarinna Almodovar, Wade T. Iams, Catherine B. Meador, Zhiguo Zhao, Sally York
Journal of Thoracic Oncology. 2018-01-01 - 67 citationsMismatch Repair-dependent Iterative Excision at Irreparable O6-Methylguanine Lesions in Human Nuclear ExtractsSally J. York, Paul Modrich
The Journal of Biological Chemistry. 2006-08-11 - 10 citationsBlood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage DiseaseWade T. Iams, Prasad R. Kopparapu, Yingjun Yan, Anel Muterspaugh, Zhiguo Zhao
JTO Clinical and Research Reports. 2020-06-01
Press Mentions
VICC Helps Expand Cancer Patient’s Treatment OptionsJanuary 14th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
